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Background: The diagnostic and prognostic value of microRNA (miRNA) expression aberrations in pancreatic
ductal adenocarcinoma (PDAC) has been studied extensively in recent years. However, differences in measurement
platforms and lab protocols as well as small sample sizes can render gene expression levels incomparable.
Methods: A comprehensive meta-review of published studies in PDAC that compared the miRNA expression
profiles of PDAC tissues and paired neighbouring noncancerous pancreatic tissues was performed to determine
candidate miRNA biomarkers for PDAC. Both a miRNA vote-counting strategy and a recently published Robust Rank
Aggregation method were employed. In this review, a total of 538 tumour and 206 noncancerous control samples
were included.
Results: We identified a statistically significant miRNA meta-signature of seven up- and three down-regulated
miRNAs. The experimental validation results showed that the miRNA expression levels were in accordance with the
meta-signature. The results from the vote-counting strategy were consistent with those from the Robust Rank
Aggregation method. The experimental validation confirmed that the statistically unique profiles identified by the
meta-review approach could discriminate PDAC tissues from paired nonmalignant pancreatic tissues. In a cohort of
70 patients, the high expression of miR-21 (p=0.018, HR=2.610; 95% CI=1.179-5.777) and miR-31 (p=0.039, HR=2.735;
95% CI=1.317-6.426), the low expression of miR-375 (p=0.022, HR=2.337; 95% CI=1.431-5.066) were associated with
poor overall survival following resection, independent of clinical covariates.
Conclusions: The identified miRNAs may be used to develop a panel of diagnostic and prognostic biomarkers for
PDAC with sufficient sensitivity and specificity for use in a clinical setting.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the
most aggressive of all malignancies [1]. Less than 20% of
PDAC patients present with localised, potentially curable
tumours. The overall 5-year survival rate is <5%. Because
the chemotherapeutic options prolong life only minim-
ally, the current PDAC mortality is nearly identical to its
incidence [2]. Extensive studies have been performed to* Correspondence: gongweius@hotmail.com; zhiwquan@163.com
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reproduction in any medium, provided the oridentify biomarkers for this disease. At the messenger
RNA (mRNA) level, quite a few, including some very
specific molecular variations have been found in cancer-
ous tissues [3]. MicroRNAs (miRNAs), a class of short
non-coding RNA molecules that range in size from 19
to 25 nucleotides, have been proposed as promising bio-
markers of early cancer detection and accurate prognosis
as well as targets for more efficient treatment [4,5].
MiRNAs play important roles in regulating the transla-
tion of many genes and the degradation of mRNAs
through base pairing to partially complementary sites,
predominately in the 3′ untranslated region [6,7]. Sev-
eral studies have implicated miRNAs in the regulation of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ily quantifiable and associate strongly with clinical out-
come, and miRNAs may match these criteria.
High-throughput technologies have been employed to
identify differences in miRNA expression levels between
normal and cancerous tissues. These studies have the
potential to identify dozens or hundreds of differentially
expressed miRNAs, although only a small fraction of
them may be of actual clinical utility as diagnostic/prog-
nostic biomarkers. Finding a meaningful way in which to
combine different data sources is often a non-trivial task.
Differences in measurement platforms and lab protocols
as well as small sample sizes can render gene expression
levels incomparable. Hence, it may be better to analyse
datasets separately and then aggregate the resulting gene
lists. This strategy has been applied to identify gene co-
expression networks [11] and to define more robust sets
of cancer-related genes [12,13] and miRNAs [14,15].
In the meta-review approach, the results of several in-
dividual studies are combined to increase statistical
power and subsequently resolve any inconsistencies or
discrepancies among different profiling studies. In this
study, we applied two meta-review approaches: the well-
known vote-counting strategy [12,13], which is based on
the number of studies reporting a gene as being consist-
ently expressed and then further ranking these genes
with respect to total sample size and average fold-change,
and the recently published Robust Rank Aggregation
method [16,17]. Pathway analysis was then performed to
identify the physiological impact of miRNA deregulation
in PDAC progression. Moreover, we further validated the
most up-regulated and down-regulated miRNAs from the
meta-review in a clinical setting. The expression levels of
a subset of candidate miRNAs were assessed by quantita-
tive real-time polymerase chain reaction (qRT-PCR). With
the validation of candidate miRNAs, we selected the most
promising miRNAs based on factors such as fold-change
to explore their potential effects on the survival of PDAC
patients after surgical resection.
Materials and methods
Selection of studies and datasets
The Scopus database (www.scopus.com) was searched for
PADC miRNA expression profiling studies using search
term TITLE-ABS-KEY [(mirna* OR microrna* OR mir-*
OR mir) AND profil* AND (pancreas* cancer OR pancre-
atic carcinoma OR pancreas* neoplas* OR pancreatic tumo*
OR carcinoma of pancreas* OR cancer of pancreas*)]. The
same strategy was also applied to searches of the Gene
Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/),
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/), and
PubMed (www.ncbi.nlm.nih.gov/pubmed). The last
search was performed on May 11, 2013. The titles and
abstracts of the articles were screened, and the full textof the articles of interest was evaluated. We included
only original experimental articles that were published
in English and that compared the expression of miRNAs
in PDAC tissue and noncancerous pancreatic tissue in
humans. Articles were excluded based on the following
criteria: (i) review articles, case reports or letters; (ii)
non-English articles; (iii) studies of individual pre-
selected candidate miRNAs; (iv) studies that used RT-
PCR for initial selection (the reasons for this exclusion
criterion are explained in the Discussion section); (v)
studies using cell lines or serum from PDAC patients;
(vi) studies that did not use a miRNA microarray platform;
(vii) studies profiling different histological subtypes; (viii)
studies that did not include noncancerous tissue.
Data extraction
Two investigators (MM and XK) independently evalu-
ated and extracted the data using standard protocols,
and all discrepancies were resolved by a third investiga-
tor (MW). From the full text and corresponding supple-
mental information, the following eligibility items were
collected and recorded for each study: author, region,
period, selection and characteristics of the recruited
PDAC patients, platform of miRNA expression profiling,
and the list of up- and down-regulated miRNAs and
their corresponding fold-changes. When the gene list was
not available, the authors were contacted directly. All




The miRNAs were ranked according to their importance
as follows: (i) number of comparisons in agreement (i.e.,
listing the same miRNAs as having a consistent direction
of change and being differentially expressed, respect-
ively); (ii) total number of samples for comparison in
agreement; (iii) average fold-changes reported for com-
parisons in agreement. Total sample size was considered
more important than average fold-change because many
studies did not report a fold-change. Furthermore, the
average fold-change was based solely on the subset of
studies for which a fold change value was available.
Robust rank aggregation method
The list of extracted miRNAs was ranked based on
their associated p-values (less than 0.05 was consid-
ered significant) when their fold-changes were not
reported. All of the protocols for the Robust Rank
Aggregation method are free to download at the
comprehensive R Archive Network website (http://cran.
r-project.org/). Details can be found in the package
documentation (http://cran.r-project.org/web/packages/
RobustRankAggreg/RobustRankAggreg.pdf). This method
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which indicates how much better it is ranked compared
with a null model, expecting random ordering. To assess
the stability of the acquired p-values, leave-one-out cross-
validation was applied in the Robust Rank Aggregation
algorithm. This analysis was repeated 10,000 times, and
each time, one random gene list was left out of the ana-
lysis. The p-values acquired from each round for each
miRNA were then averaged.MiRNA target prediction and enrichment analysis
The mRNA targets of the miRNA genes were predicted
using TargetScan (http://www.targetscan.org/), miRDB
(http://mirdb.org/miRDB/), and miRANDA (http://www.
microrna.org/microrna/getGeneForm.do), as each algo-
rithm determines target binding differently. We selected
targets from the miRANDA/miSVR search with scores
less than −1.25 for further analysis. Enrichment analyses
for KEGG and Panther pathways and Gene Ontology
terms were performed with the GeneCodis tool (http://
genecodis.dacya.ucm.es/). The potential targets of each
miRNA were used as input.Figure 1 PRISMA 2009 flow chart. Only original experimental articles tha
miRNA expression between PDAC tissue and noncancerous pancreatic tissu
not use a miRNA microarray platform or if they profiled miRNAs in differenEthics statement
Ethical approval for this study was obtained from the
Department of General Surgery of Ruijin Hospital at
Shanghai Jiaotong University (Shanghai, China). All pa-
tients provided informed written consent for their
tissues to be used for scientific research and to publish
their case details.
Sample collection
Seventy-eight PDAC tissue samples and neighbouring
noncancerous pancreatic tissue samples (collected post-
operatively from September 2010 to August 2011) used
in this study were obtained from the Department of Gen-
eral Surgery of Ruijin Hospital at Shanghai Jiaotong Uni-
versity (Shanghai, China). The specimens were obtained
from patients undergoing PDAC resection with curative
intent. All diagnoses were based on pathological and/or
cytological evidence. The histological features of the
specimens were evaluated by a senior pathologist
according to the WHO (World Health Organization)
classification criteria. The tissues were obtained before
chemotherapy and radiation therapy. Upon removal of
the surgical specimen, research personnel immediatelyt were published in English and that analysed the differences in
e in humans were included. Articles were excluded if the studies did
t histological subtypes.
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Pathology faculty performed a gross analysis of the spe-
cimen and selected pancreatic tissues that appeared to
be cancerous and pancreatic tissues that appeared to be
normal for analysis. Each sample was immediately fro-
zen in liquid nitrogen and stored at −80°C prior to RNA
isolation and qRT-PCR analysis. A second level of
quality control was performed on the adjacent benign
tissues. Histological slides were prepared from the sec-
tion of frozen tissue that was directly adjacent to the tis-
sue from which the RNA was isolated. These slides were
examined by experienced pathologists to determine if
the benign tissues contained any pancreatic tumour
cells. Benign tissues that contained residual tumour tis-
sues were not included in the study. Complete clinico-
pathological follow-up data of the PDAC patients from
which the specimens were collected were available.
Validation of the most up-regulated or down-regulated
miRNAs using qRT-PCR
Total RNA was isolated from the frozen tissue sample
with TRIzol (Invitrogen) according to the manufac-
turer’s instructions. First-strand complementary DNA
(cDNA) was synthesised from 2 μg of the total RNA
using an oligo-dT primer and superscript II reverse
transcriptase (Invitrogen). Then, quantification of the
most up-regulated or down-regulated miRNAs was
performed by qRT-PCR using SYBRR Premix Ex Taq
(TakaRa). The U6 primers were obtained from TakaRa.
PCR was performed in a real-time PCR system (Bio-
Rad) as follows: 95°C for 3 min, followed by 35 cycles of
95°C for 5 sec, 60°C for 20 sec and 72°C for 30 sec, and
then 94°C for 1 min and 60°C for 1 min, with an in-
crease of 0.5°C per cycle. The expression level values
were normalised to those of the small nuclear RNA U6
as a control. Relative fold-changes of miRNA expressionTable 1 Eleven microarray-based miRNA expression profiling
First author (reference) Acronym Region Assay ty
AE Szafranska [21] AE USA Custom micr
Ada Piepoli [22] AP Italy Affymetrix Gene
Andrea S.Bauer [23] AS Germany Geniom biochip miRN
Eun Joo Lee [24] EJ USA Agilent Human miR
Mark Bloomston [25] MB USA Custom miRNA
Nicolai A.Schultz [26] NA Denmark TaqMan array human micro
Nigel B.Jamieson [27] NB USA Agilent Human miRNA Mic
Nicole C.Panarelli [28] NC USA FlexmiR miRNA
S Ali [29] SA USA LC Science Housto
Shuyu Zhang [30] SZ China Exiqon miRCURY
Yuichi Nagao [31] YN Japan Toray 3D-Gene miRN
Abbreviations: NR not reported, pairs, cancerous and normal samples from the samwere calculated using the △△CT method, and the values
were expressed as 2-△△CT. The primer sequences were as
follows: U6, 5′-CTCGCTTCGGCAGCACA-3′ (for-
ward), 5′-AACGCTTCACGAATTTGCGT-3′ (reverse);
miR-155, 5′-cgGCGGTTAATGCTAATCGTG-3′ (for-
ward), 5′-GTGCAGGGTCCGAGGT-3′ (reverse); miR-
100, 5′-GAATTCCCATACTGGTTGGCTCCCGC-3′
(forward), 5′-CTCGAGACGAATTCAATCGAAATAT
TC-3′ (reverse); miR-21, 5′-ACACTCCAGCTGGGT
AGCTTATCAGACTGA-3′ (forward), 5′-TGGTGTCG
TGGAGTCG-3′ (reverse); miR-221, 5′-CCCAGCATT
TCTGACTGTTG-3′ (forward), 5′-TGTGAGACCATT
TGGGTGAA-3′ (reverse); miR-31, 5′-ACGCGGCAA
GATGCTGGCA-3′ (forward), 5′-CAGTGCTGGGTCC
GAGTGA-3′ (reverse); miR-143, 5′-CCTGGCCTGAG
ATGAAGCAC-3′ (forward), 5′-CAGTGCTGGGTCCG
AGTGA-3′ (reverse); miR-23a, 5′-CTTGAACTCCTG
GCCTGAAG-3′ (forward), 5′-GCCAAAGAAACACTC
ACAGCT-3′ (reverse); miR-217, 5′-GCGTACTGCATC
AGGAACTGATTGGA-3′ (forward), 5′-GGGCACACA







Kaplan-Meier survival analysis was used to analyse the as-
sociation between postoperative survival and the miRNA
expression level measured by qRT-PCR, and the resulting
curves were divided into two classes (high and low expres-
sion in comparison to the mean level of miRNA expres-
sion as the threshold). Survival analysis was performed for
each clinical covariate to assess their influence on out-
come using a log-rank test. A multivariate Cox regressionstudies of human PDAC tissues
pe No. of probes No. of samples (cancer/normal)
oarray 377 13 (8/5)
Chip array 866 NR (cancer=17)
A homo sapiens NR 110 (94/16)
NA Microarray NR 28 (15/13)
microarray 1100 130 (65/65), 65 pairs
RNA A+B Cards v2.0 664 188 (160/28)
roarray (version 2.0) 723 58 (48/10)
microarray 328 27 (17/10)
n microarray NR 44 (29/15)
LNA array 1200 40 (20/20), 20 pairs
A microarray >900 79 (65/24)
e patient.
Table 2 Up-regulated miRNAs (n=50) reported in at least two expression profiling studies
miRNA name Studies with the same direction (reference) No. of tissue samples tested Mean fold-change Mean rank
hsa-miR-155 AE, AP, AS, EJ, MB, NB, NC, YN 329 4.98 12.62
hsa-miR-21 AE, MB, NA, NB, NC, SZ, YN 376 2.95 12.29
hsa-miR-100 AE, AS, EJ, MB, NB, NC, YN 317 8.07 13.00
hsa-miR-221 AE, AP, AS, EJ, MB, NB, NC 264 6.71 11.42
hsa-miR-31 AE, AP, AS, NA, YN 344 5.44 10.00
hsa-miR-10a AE, AS, MB, NB, YN 280 2.50 14.60
hsa-miR-23a AE, AP, AS, MB, NB 229 3.46 22.60
hsa-miR-143 AE, AP, MB, NB, YN 203 4.03 9.40
hsa-miR-222 AE, AS, MB, NB, YN 199 2.77 11.20
hsa-miR-210 AE, AS, MB, NA 323 2.97 16.00
hsa-miR-125a-5P AE, AP, AS, MB 184 2.98 22.50
hsa-miR-145 AE, AP, AS, NB 167 3.75 9.75
hsa-miR-181a AS, MB, NB 207 4.83 13.33
hsa-miR-199a-3p AP, AS, YN 176 3.59 9.33
hsa-miR-23b AS, AP, MB 176 3.09 42.33
hsa-miR-181b AE, AS, MB 167 2.71 14.67
hsa-miR-199b-3p AE, AS, NB 159 3.83 14.33
hsa-miR-331-3p AP, AS, NB 159 1.83 35.33
hsa-miR-150 AE, AS, NB 150 3.73 6.67
hsa-let-7i AE, AS, NB 150 2.47 17.33
hsa-miR-214 AE, AS, NB 147 3.63 11.00
hsa-miR-1246 AP, AS, SA 140 3.37 42.67
hsa-miR-223 AE, MB, NB 121 3.71 6.67
hsa-miR-24 AE, AP, NB 70 2.50 26.67
hsa-miR-584 AS, NA 254 5.81 64.50
hsa-miR-886-5p AS, NA 254 3.26 38.50
hsa-miR-205 MB, NA 225 11.04 12.50
hsa-miR-142-3p NA, NB 208 4.17 23.50
hsa-miR-451 NA, SA 189 28.36 16.00
hsa-miR-939 AP, NA 177 4.76 22.50
hsa-miR-196b AE, NA 173 11.93 3.00
hsa-miR-99a AS, YN 159 2.07 60.00
hsa-miR-181c AS, MB 159 4.49 9.50
hsa-miR-199a-5p AS, NB 142 2.64 18.50
hsa-miR-505 AS, NB 142 1.87 34.50
hsa-miR-342-3p AS, NB 142 1.67 55.50
hsa-miR-140-3p AS, NB 142 1.58 61.00
hsa-miR-34a AS, NB 142 1.31 56.50
hsa-miR-92a AS, SA 123 6.64 10.00
hsa-miR-320a AS, SA 123 2.05 28.50
hsa-let-7e AP, AS 111 4.31 36.50
hsa-miR-92b AP, AS 111 1.66 47.50
hsa-miR-224 AE, AS 102 1.32 59.00
hsa-miR-99b AE, AS 102 1.31 53.50
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Table 2 Up-regulated miRNAs (n=50) reported in at least two expression profiling studies (Continued)
hsa-miR-93 AE, AS 98 1.83 21.50
hsa-miR-125b-1 EJ, MB 80 12.62 16.50
hsa-miR-106b AE, NB 61 1.33 36.00
hsa-miR-27a AE, NB 49 2.70 22.00
hsa-miR-17 AP, SA 42 2.77 14.50
hsa-miR-125b AE, AS 25 1.89 22.00
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the hazard ratio (HR) with a 95% confidence interval (CI)
was reported as an estimate of overall survival risk. The
variables that were found to be significant in univariate
analysis at p<0.05 were included in the final multivariate
analysis in a backwards stepwise fashion. The statistical
analyses were performed using the SPSS 18.0 for
Windows software package (SPSS Inc.). DifferencesTable 3 Down-regulated miRNAs (n=27) reported in at least t
miRNA name Studies with same direction (reference) No
hsa-miR-217 AE, AS, NA, NB, YN
hsa-miR-148a AE, AS, MB, NA, NB
hsa-miR-375 AE, AS, MB, NA, NB
hsa-miR-216b AS, NA, NB, YN
hsa-miR-216a AS, NA, NB, YN
hsa-miR-130b AE, AS, NA, NB
hsa-miR-141 NB, SZ, AE, AS
hsa-miR-30a-3p NA, NB, AE
hsa-miR-200c AE, AS, NB
hsa-miR-30a-5p AS, NB, AE
hsa-miR-29c AE, AS, NB
hsa-miR-30d AE, AS, NB
hsa-miR-30e AS, NB, AE













hsa-let-7b AE, SAwere considered to be statistically significant when the
p-value was <0.05.
Results
Five hundred and ninety-eight relevant publications were
indexed in the databases mentioned above (Scopus,
GEO, PubMed and ArrayExpress). According to the in-
clusion criteria and the identification of duplicatewo expression profiling studies




























Table 4 Differentially expressed miRNAs (n=21) with an inconsistent direction between two studies
miRNA name Direction of expression Studies with same direction
(reference)
No. of tissue samples
tested
Mean fold-change Mean rank
hsa-miR-103 ↑ AE, AP, AS, NB 167 2.72 87.00
↓ SZ 20 1.73 5.00
hsa-let-7d ↑ EJ, AP 32 6.82 11.50
↓ SA, AE 37 7.04 22.50
hsa-miR-26a ↑ AP 17 5.16 12.00
↓ AE, AS, SA 131 4.38 30.67
hsa-miR-146a ↑ AE, AS 102 2.08 12.00
↓ SA 29 3.03 9.00
hsa-miR-708 ↑ AS, NA 254 3.15 43.50
↓ NB 48 9.26 7.00
hsa-miR-345 ↑ AS 94 1.45 85.00
↓ EJ, NB 63 12.59 2.50
hsa-miR-376a ↑ EJ 15 7.79 17.00
↓ AE, AS 102 1.43 28.00
hsa-miR-494 ↑ NA 160 4.23 41.00
↓ NB, AE 56 3.86 14.50
hsa-miR-423-5p ↑ SA 29 9.03 4.00
↓ YN, NB 113 2.77 30.00
hsa-miR-365 ↑ SZ 20 1.75 2.00
↓ AE, AS 102 1.80 17.00
hsa-miR-130a ↑ NB 48 2.00 28.00
↓ AE, AS 102 1.62 29.50
hsa-miR-132 ↑ AS 94 2.59 18.00
↓ SZ 20 3.05 1.00
hsa-miR-324-3p ↑ AS 94 1.95 39.00
↓ NB 48 2.16 50.00
hsa-miR-501-5p ↑ AS 94 1.59 64.00
↓ NB 48 2.02 52.00
hsa-miR-874 ↑ AS 94 1.49 80.00
↓ NB 48 2.20 47.00
hsa-miR-518d-3p ↑ AS 94 1.30 103.00
↓ NA 160 15.35 9.00
hsa-miR-28-3p ↑ AS 94 1.28 104.00
↓ NB 48 4.49 23.00
hsa-miR-648 ↑ NA 160 8.63 16.00
↓ NB 48 9.07 8.00
hsa-miR-575 ↑ NA 160 7.52 22.00
↓ NB 48 4.38 24.00
hsa-miR-877 ↑ NA 160 4.03 43.00
↓ NB 48 3.48 28.00
hsa-let-7g ↑ NB 48 2.44 21.00
↓ AE 8 1.06 45.00
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Table 5 PDAC meta-signature from the vote-counting
strategy (reported consistently in at least five studies)
miRNA name No. of studies Mean fold-change Mean rank
Up-regulated
hsa-miR-155 8 4.98 12.62
hsa-miR-21 7 2.95 12.29
hsa-miR-100 7 8.07 13.00
hsa-miR-221 7 6.71 11.42
hsa-miR-31 5 5.44 10.00
hsa-miR-10a 5 2.50 14.60
hsa-miR-23a 5 3.46 22.60
hsa-miR-143 5 4.03 9.40
hsa-miR-222 5 2.77 11.20
Down-regulated
hsa-miR-217 5 18.16 4.20
hsa-miR-148a 5 8.03 7.00
hsa-miR-375 5 4.86 9.40
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were included. However, one article was excluded for
the unavailability of a ranked gene list both publically
and in response to a request from the corresponding au-
thor [18]. The selection process is shown in Figure 1.
Among the analysed studies, some of the studies
employed patient samples as low as 5 [19] or 3 [20],
which was too small to provide any reliable data. Not
surprisingly, these two studies [19,20] were the basis for
excluding numerous candidates that were consistently
reported as either up- or down-regulated in other stud-
ies. The most glaring example of the strategic error of
including these two studies in our meta-analysis is








hsa-miR-155 6.17E-11 8.64E-13 8
hsa-miR-100 3.32E-09 7.01E-11 7
hsa-miR-21 2.75E-09 3.29E-11 7
hsa-miR-221 1.56E-08 9.34E-10 7
hsa-miR-31 1.44E-05 8.83E-07 5
hsa-miR-143 6.78E-04 4.56E-06 5
hsa-miR-23a 3.27E-03 5.09E-05 5
Down-regulated
hsa-miR-217 7.56E-07 4.37E-09 5
hsa-miR-148a 2.00E-05 3.55E-07 5
hsa-miR-375 1.08E-03 8.70E-06 5regulated in 7 studies [21,23,24,26,28,29,31], was con-
sidered to be down-regulated in one of the aforemen-
tioned studies [19], which only employed 5 tumour
samples. Therefore, if Ref 19 was included, miR-100
would be listed as a miRNA with an inconsistent direc-
tion and would be subsequently excluded from the list
of most consistently reported miRNAs. In addition, the
fold-change in this study [19] was very low (less than 2)
and may not have been significant if a large sample size
was analysed. Other examples include miR-145, miR-
141, miR-379, miR-200c, and miR-125b, which were
reported in an opposite direction solely in these two
studies. To avoid these deviations, these two small-
sample-size studies were excluded from our meta-
analysis. A brief description of the eleven included stud-
ies [21-31] and the acronyms by which the studies are
referred to in the following text are provided in Table 1.
The number of patients with PDAC that were investi-
gated in these eleven studies ranged from 8 to 160 (median
47). The studies employed a diversity of microarray plat-
forms (either commercial or custom), and the average
number of miRNAs assayed was 778 (ranging from 377 to
1200; data were missing in three papers [23,24,29]).
Only five studies [21-23,26,27] provided the whole list
of differentially expressed miRNAs, while the others
presented only a portion of their data. Our pooled
dataset included a total of 538 tumour samples and 206
noncancerous control samples (at least), as in some
studies, the number of noncancerous control samples
was not specified [22].
A total of 439 differentially expressed miRNAs were
reported in the eleven miRNA expression profiling stud-
ies; 254 were up-regulated and 185 were down-regulated
in at least one study. Among the 439 miRNAs, 98 were
reported in at least two studies; 77 (78.57%) with a consist-
ent direction (Tables 2 and 3) and 21 with an inconsistent
direction (Table 4) among the studies. Among the 77
miRNAs with a consistent direction, 50 were reported to
be up-regulated (Table 2) and 27 were reported to be
down-regulated (Table 3). One miRNA (miR-155) was
reported in eight studies, three miRNAs (miR-21, miR-100
and miR-221) were reported in seven studies and twelve
miRNAs were reported in at least five studies, with a con-
sistent direction in all reports (Table 5). The miRNAs that
were consistently reported in at least five studies are
shown in Table 5. Although there were no strong disagree-
ments between the individual miRNA profiling studies,
the top lists varied considerably from study to study.
Using the Robust Rank Aggregation method, we
identified a statistically significant meta-signature of 7
up- and 3 down-regulated miRNAs in PDAC samples
compared to noncancerous pancreatic tissues (Table 6).
All meta-signature miRNAs that reached statistical
significance after Bonferroni correction were reported
Table 7 The ten most strongly enriched GO processes





















0006915: apoptotic process 1.76E-09 57
0045892: negative regulation of
transcription, DNA-dependent
4.03E-09 55
0007155: cell adhesion 5.06E-08 90
0007411: axon guidance 9.83E-08 24
KEGG Pathways
Pathway Hyp* Genes
05200: Pathways in cancer 1.84E-05 33
04010: MAPK signalling pathway 3.62E-05 31
04144: Endocytosis 1.89E-04 19
04510: Focal adhesion 2.34E-04 25












04310: Wnt signalling pathway 5.29E-03 14
04520: Adherens junction 5.68E-03 10
Panther pathways
Pathway Hyp* Genes










P00021: FGF signalling pathway 8.83E-04 14




P00048: PI3 kinase pathway 5.06E-03 8
Table 7 The ten most strongly enriched GO processes





P04393: Ras pathway 7.82E-03 10
The number of predicted target genes in the process or pathway is shown.
Hyp*: corrected hypergeometric p-value.
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miRNAs belong to the broadly conserved seed family
(conserved across most vertebrates and bony fish).
Our results from the vote-counting strategy were al-
most the same with those from the Robust Rank Aggre-
gation method. The ten GO processes and pathways that
were most strongly enriched with respect to the meta-
signature miRNA candidates (miR-155, miR-100, miR-21,
miR-221, miR-31, miR-143, miR-23a, miR-217, miR-148a
and miR-375) are shown in Table 7.
Experimental validation of the expression levels of the
most deregulated miRNAs in patients with PDAC
To determine if the ten most deregulated miRNAs from
the meta-analysis (miR-155, miR-100, miR-21, miR-221,
miR-31, miR-143, miR-23a, miR-217, miR-148a and miR-
375) could be used as diagnostic biomarkers of PDAC, the
expression levels of these miRNAs were compared be-
tween PDAC tissues and neighbouring noncancerous tis-
sues by qRT-PCR analysis. The results showed that the
expression levels of miR-155, miR-100, miR-21, miR-221,
miR-31, miR-143 and miR-23a were increased, whereas
the levels of miR-217, miR-148a and miR-375 were de-
creased in the PDAC tissues (all p<0.05). Detailed data are
available in Table 8.
Determination of prognostic significance of the candidate
miRNAs in PDAC
The clinicopathological characteristics of 78 PDAC pa-
tients are shown in Table 9. The expression levels of
individual miRNAs along with other well-known poten-
tial prognostic clinicopathological factors, such as hist-
ology, T category, lymph node metastasis, tumour size,
perineural invasion, venous invasion and margin were
included in a univariate analysis. With respect to the
miRNA expression levels, for the up-regulated miRNAs,
a fold-change of ≥2 was defined as high expression, and
a fold-change of <2 was defined as low expression; for
the down-regulated miRNAs, a fold-change of ≥2 was
defined as low expression, and a fold-change of <2 was
defined as high expression. Patients with advanced
disease (UICC stage IV and concomitance of distant me-
tastases) were excluded because we assumed that the
prognosis of these patients (n=8) is determined by the
occurrence of relapse or metastasis rather than other
Table 8 Relative expression of miRNAs in PDAC compared
with matched normal pancreatic tissue controls
determined by qRT-PCR
miRNA name
Up-regulated PDAC N p-value Fold-change
miR-155 5.56±1.00 2.71±0.66 <0.001 2.11±0.41
miR-100 7.40±2.21 3.91±1.32 <0.001 2.00±0.51
miR-21 3.80±0.99 1.7±0.35 <0.001 2.25±0.44
miR-221 8.03±2.77 3.26±0.67 <0.001 2.53±0.84
miR-31 6.52±0.98 2.93±0.39 <0.001 2.12±0.47
miR-143 7.45±1.22 2.21±1.43 <0.001 2.94±0.74
miR-23a 7.80±1.18 3.44±0.73 <0.001 2.35±0.52
Down-regulated
miR-217 2.88±1.15 10.35±3.68 <0.001 3.91±1.36
miR-148a 3.85±1.48 10.39±2.97 <0.001 2.86±0.77
miR-375 4.00±1.55 7.05±1.99 <0.001 1.76±0.36
Data are expressed as the mean ± SD. N: matched normal pancreatic tissue.

















≥2 cm 42 (54%)
<2 cm 36 (46%)
Histology
Well or moderately differentiated 38 (49%)
Poorly differentiated 40 (51%)
Perineural invasion
None or slight 46 (59%)
Prominent 32 (41%)
Venous invasion
None or slight 40 (51%)
Prominent 38 (49%)
Tumour grade (UICC)
Stage I-IIA 32 (41%)
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levels.
Kaplan-Meier survival analysis was used to analyse the
association between postoperative survival and the miRNA
expression level, and the resulting curves were divided into
two classes (high and low expression in comparison with
the mean level of miRNA expression as the threshold), as
shown in Figure 2.
A univariate analysis using the Cox hazard regression
model demonstrated that a high expression level of miR-21
(p=0.018, HR=2.610; 95% CI=1.179-5.777) and miR-155
(p=0.035, HR=2.414; 95% CI=1.064-5.478), a low expression
level of miR-375 (p=0.022, HR=2.337; 95% CI=1.431-5.066),
T category (p=0.039, HR=2.282; 95% CI=1.043-4.994) and
margin involvement (p=0.026, HR=2.550; 95% CI=1.120-
5.805) are associated with poor patient survival.
Identification of two prognostic miRNAs by multivariate
analysis
In a multivariate analysis using the Cox hazard regres-
sion model, a high expression level of miR-21 (p=0.021,
HR=2.599; 95% CI=1.151-5.867), a low expression level
of miR-375 (p=0.034, HR=2.451; 95% CI=1.429-5.135) and
margin involvement (p=0.030, HR=2.543; 95% CI=1.093-
5.918) were identified as significant unfavourable prognos-
tic factors (Table 10).
Discussion
The common drawback of miRNA expression profiling
studies is the lack of agreement among several studies.
Differences in measurement platforms and lab protocols
as well as small sample sizes can render gene expression
levels incomparable. Sato et al. [32] and Wang et al. [33]
systematically analysed representative miRNA profilingplatforms and revealed that each platform is relatively
stable in terms of its own intra-reproducibility; however,
the inter-platform reproducibility among different plat-
forms is low. Although the ideal method involves the
analysis the raw miRNA expression datasets that are
pooled together, such a rigorous approach is often im-
possible due to the unavailability of raw data and the
low inter-platform concordance of results among differ-
ent studies would bring difficulties to the analysis. To
overcome these limitations, it might be better to analyse
datasets separately and then aggregate the resulting gene
lists. In this study, we used a meta-analysis approach to
analyse PDAC-specific miRNAs derived from independent
Ma et al. Journal of Experimental & Clinical Cancer Research 2013, 32:71 Page 11 of 14
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strategy [12,13] and the recently published Robust Rank
Aggregation method [16,17] were employed. The core ele-
ments of the two methods were searches for the most
recognised miRNAs among the included studies.
Two principal methods are used to measure miRNA
expression levels: qRT-PCR and microarray hybridisa-
tion. The technological merits and drawbacks of qRT-
PCR and microarrays for miRNA analysis are similar to
those for RNA or genomic DNA quantification [34]. RT-
PCR, a semiquantitative method, is labour intensive and
provides data for only one, or very few, miRNA(s) per
assay. However, the rapid increase in the number of
known miRNAs renders this method inefficient on a
genomic scale, and it is most likely better used as a tool
for validation rather than discovery. Microarrays are the
best option for a standardised genome-wide assay that isFigure 2 Kaplan-Meier analysis of overall survival in patients with PD
(C), miR-221 (D), miR-31 (E), miR-143 (F), miR-23a (G), miR-217 (H), miamenable to high-throughput application [35]. As qRT-
PCR detects only preselected miRNAs, mostly the
miRNAs that were shown to be differentially expressed
in PDAC from normal tissue in other studies, it hinders
the discovery of new miRNAs. Most importantly, the re-
sults of studies using qRT-PCR analysis [36-40] were con-
sistent with those of microarray-based studies. In addition
to the intra-platform deviations between microarray and
qRT-PCR analyses [35], we excluded qRT-PCR-based
studies and focused on studies using miRNA microarray
platforms.
We identified a meta-signature of seven up- and three
down-regulated miRNAs. To our knowledge, no meta-
analysis of miRNA profiling studies has specifically in-
vestigated PDAC. Furthermore, this is the first study that
used a combination of the two most commonly used
methods in the meta-analysis of miRNA and geneAC based on their expression of miR-155 (A), miR-100 (B), miR-21
R-148a (I) and miR-375 (J). p-values are based on the log-rank test.
Table 10 Univariate and multivariate survival analysis of the clinicopathological and molecular features of PDAC
Factor Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Histology Well or moderate vs. poor 1.342 (0.621–2.901) 0.454
T category T 1/2 VS. T 3/4 2.282 (1.043–4.994) 0.039 1.518 (0.666–3.460) 0.320
Lymph node metastasis Negative vs. positive 1.935 (0.867–4.317) 0.107
Tumour size <2 cm vs. ≥2 cm 1.736 (0.790–3.814) 0.170
Perineural invasion None or slight vs. prominent 1.244 (0.563–2.752) 0.589
Margin involvement R0 vs. R1 2.550 (1.120–5.805) 0.026 2.543 (1.093–5.918) 0.030
Vascular invasion None or slight vs. prominent 2.542 (1.154–5.601) 0.021 1.940 (0.819–4.597) 0.132
miR-155 expression High vs. low 2.414 (1.064–5.478) 0.035 1.365 (0.520–3.579) 0.538
miR-100 expression High vs. low 1.480 (0.683–3.205) 0.321
miR-21 expression High vs. low 2.610 (1.179–5.777) 0.018 2.599 (1.151–5.867) 0.021
miR-221 expression High vs. low 2.001 (0.868–4.617) 0.104
miR-31 expression High vs. low 2.735 (1.317-6.426) 0.039 2.637 (1.298-6.635) 0.048
miR-143 expression High vs. low 1.516 (1.211–4.429) 0.257
miR-23a expression High vs. low 1.639 (0.709–3.788) 0.248
miR-217 expression Low vs. high 1.419 (1.045-4.021) 0.205
miR-148a expression Low vs. high 1.739 (1.385-4.481) 0.093
miR-375 expression Low vs. high 2.337 (1.431-5.066) 0.022 2.451 (1.429-5.135) 0.034
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used as diagnostic biomarkers, we experimentally vali-
dated the expression of these miRNAs in a set of PDAC
samples.
There are several factors that must be considered
when choosing miRNAs as candidate diagnostic bio-
markers for PDAC. First, the fold-change of the bio-
marker should be significant enough to discriminate
cancerous tissue from benign tissue. As is shown in
Tables 2 and 3, the average fold changes of the 10 miRNAs
identified in the microarray-based studies were all >2. In
addition, the candidate miRNAs should be expressed in a
majority of tissues. As was validated by qRT-PCR, the up-
regulated miRNAs were all expressed in more than 85% of
the samples tested (data not shown).
Second, the biological function of each individual
miRNA should be thoroughly investigated. A single
miRNA may have dozens of targets, and a specific mRNA
may be regulated by multiple different miRNAs [7]. A bet-
ter understanding of the targets of the miRNAs would ad-
vance their use in clinical settings. As shown in Table 7,
the ten most strongly enriched GO processes and pathways
with respect to the meta-signature miRNA candidates were
identified. In the GO processes list, regulation of transcrip-
tion, DNA-dependent; positive regulation of transcription
from RNA polymerase II promoter; and positive regulation
of transcription, DNA-dependent were ranked as the top
three, which is in accordance with the known primary
functions of miRNAs [6,7]. Pathways in cancer and Wnt
signalling pathways were ranked first in the KEGG andPanther pathway lists, respectively, highlighting the essen-
tial roles of miRNAs in cancer development.
Third, there should be adequate information about the
pattern of expression of the miRNAs in different types
of specimens. It has been indicated that circulating
miRNAs in plasma could be more tissue-specific than
tumour-specific [41,42]. In the context of the vast incon-
sistency between tissue-based and plasma-based results
[23], we focused on studies that analysed miRNA ex-
pression between PDAC tissues and noncancerous pan-
creatic tissues in humans.
Last but not least, rigorous validation and demonstra-
tion of reproducibility in an independent cohort of pa-
tients are necessary to confirm the diagnostic value of
miRNAs. With this in mind, we experimentally validated
10 candidate miRNAs in PDAC samples and confirmed
that these 10 miRNAs were differentially expressed be-
tween PDAC tissues and noncancerous pancreatic tissues.
Considering that miRNA expression is able to success-
fully discriminate normal from cancerous pancreatic tis-
sues, it is tempting to speculate that miRNAs could also
predict cancer prognosis. However, our results do not
exclude the possibility that other miRNAs are associated
with prognosis, as we only studied a meta-signature of
10 miRNAs in a limited number of PDAC samples
(n=78). The main reason for the possible association be-
tween miRNAs not within this meta-signature and prog-
nosis may centre on the relatively small sample size in
our study and others [25,27]. It is quite unrealistic to in-
clude all the miRNAs in Kaplan-Meier survival analyses,
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commonly, only the candidate miRNAs with the greatest
fold changes are included. As mentioned above, although
there were no strong disagreements between the individual
miRNA profiling studies, the top lists varied considerably
from study to study. To remedy this problem, it was critical
to identify the most differentially expressed miRNAs. We
used a meta-review approach, which combines the results
of several individual studies to increase statistical power
and to subsequently resolve the inconsistency among dif-
ferent profiling studies. A meta-signature of seven up- and
three down-regulated miRNAs was identified. Then, in in-
dependent patient samples, miR-21, miR-31 and miR-375
were found to be associated with cancer prognosis.
From our point of view, great caution should be taken
in future research in this field. To start, sample sizes
should be increased to minimise random sampling error.
Next, as it is impossible for every researcher to use the
same platform, reliable microarray platforms should be
employed in all experiments. Finally, it is advisable to
obtain an integrated view of the candidate miRNAs from
many studies to avoid one-sided opinions, as great dis-
crepancies exist among the studies.
Our study presents a method to resolve the differences
that exist among studies and might have some clinical
significance for research on miRNAs in PDAC. The 10
identified miRNAs may be used as diagnostic biomarkers
or even therapeutic targets. In addition to our meta-
analysis, we performed further studies examining the ex-
pression of the candidate miRNAs in PDAC samples and
confirmed miR-21, miR-31 and miR-375 as potential
prognostic biomarkers for PDAC.
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